Lee, J.M., Sharifi, M., and Oshman, L
While anecdotal reports and preliminary research suggest a potential connection between GLP-1 medications and decreased alcohol consumption, these agents are not FDA-approved for treating alcohol use disorder
The Salehpour study showed decreased BMI and improved insulin resistance markers metabolic improvements that create conditions for weight management, not a shortcut around it
While it is true that some individuals may experience an increase in blood pressure when starting semaglutide, this is usually temporary and resolves over time
In the second trial, SURPASS-2, tirzepatide administered at doses of 5 mg, 10 mg, or 15 mg showed superior efficacy compared to semaglutide (1 mg) in reducing body weight and HbA1c levels over 40 weeks in patients with T2DM inadequately controlled with metformin [66]
2017;312(3):E211-E220